Emergent BioSolutions | EBS - Trade Creditors


Emergent BioSolutions reported $112.2M in Trade Creditors for its fiscal quarter ending in December of 2023.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 10.9M 10.84M Dec/2025
Akebia Therapeutics USD 21.18M 11.1M Dec/2025
ALKERMES USD 107.95M 39.95M Dec/2025
Alnylam Pharmaceuticals USD 115.72M 1.87M Dec/2025
Amarin USD 45.36M 8.64M Dec/2025
ANI Pharmaceuticals USD 62.58M 7.21M Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Coherus Biosciences USD 9.91M 14.98M Dec/2025
Emergent BioSolutions USD 112.2M 500K Dec/2023
Exelixis USD 29.62M 4.27M Dec/2025
Glaxosmithkline GBP 20.72B 346.14M Dec/2025
Heron Therapeutics USD 8.99M 3.02M Dec/2025
Ionis Pharmaceuticals USD 14.33M 8.47M Sep/2025
Ironwood Pharmaceuticals USD 1.61M 224K Sep/2025
Lexicon Pharmaceuticals USD 3.08M 714K Dec/2025
Lonza CHF 471M 3M Dec/2024
Merck USD 4.15B 102M Sep/2025
Moderna USD 317M 50M Dec/2025
Myriad Genetics USD 30M 1.8M Dec/2025
Nektar Therapeutics USD 10.77M 4.79M Dec/2025
Neurocrine Biosciences USD 545.5M 425.6M Dec/2025
Pacira USD 15.15M 2.54M Dec/2025
Pfizer USD 5.02B 142M Sep/2025
PTC Therapeutics USD 45.49M 8.87M Dec/2025
Sanofi EUR 22.71B 219M Mar/2026
Sarepta Therapeutics USD 280.84M 186.83M Dec/2025
United Therapeutics USD 7.1M 460.9M Dec/2025
Vanda Pharmaceuticals USD 39.09M 33.28M Dec/2024
Xoma USD 2.65M 1.52M Sep/2025